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The use of nanotechnology based on the development and fabrication of nanostructures is one approach 
that has been employed to overcome the challenges involved with conventional drug delivery systems. 
Formulating Nanoplex is the new trend in nanotechnology. A nanoplex is a complex formed by a 
drug nanoparticle with an oppositely charged polyelectrolyte. Both cationic and anionic drugs form 
complexes with oppositely charged polyelectrolytes. Compared with other nanostructures, the yield 
of Nanoplex is greater and the complexation efficiency is better. Nanoplex are also easier to prepare. 
Nanoplex formulation is characterized through the production yield, complexation efficiency, drug 
loading, particle size and zeta potential using scanning electron microscopy, differential scanning 
calorimetry, X-ray diffraction and dialysis studies. Nanoplex have wide-ranging applications in different 
fields such as cancer therapy, gene drug delivery, drug delivery to the brain and protein and peptide  
drug delivery.
Uniterms: Nanotechnology. Nanoplex/formulation. Nanoplex/characterization. Nanoplex/applications
O uso da nanotecnologia baseada no desenvolvimento e na fabricação de nanoestruturas é uma abordagem 
que tem sido empregada para superar os desafios envolvidos nos sistemas de liberação de fármacos 
convencionais. A formulação de nanoplexos é a nova tendência na nanotecnologia. Um nanoplexo é um 
complexo formado pela nanopartícula do fármaco com poplieletrólito de carga oposta. Tanto fármacos 
catiônicos quanto aniônicos formam complexos com polieletrólitos opostamente carregados. Comparado 
com outras nanoestruturas, o rendimento dos nanoplexos é maior e a eficiência de complexação é melhor. 
Nanoplexos são, também. De mais fácil preparação. A formulação de nanoplexo é caracterizada pelo 
rendimento de produção, eficiência de complexação, carga do fármaco, tamanho de partícula e potencial 
zeta, utilizando microscopia eletrônica de varredura, calorimetria exploratória diferencial, difração de 
raios X e estudos de diálise. Os nanoplexos têm aplicações amplas em diferentes campos, como terapia 
antineoplásica, liberação em terapia gênica, liberação cerebral de fármaco, liberação de fármacos 
protéicos e peptídicos.
Unitermos: Nanotecnologia. Nanoplexos/formulação. Nanoplexos/caracterização. Nanoplexos/
aplicações.
INTRODUCTION
Nanotechnology is the science that deals with 
the nanolength scale and with processes that occur at 
the molecular level. There are a number of examples 
from nature of structures with nanodimensions such as 
red blood corpuscles (RBCs), viruses, DNA and water 
molecules (Ochekpe, 2009a). Even our history has 
a number of examples that prove we have exploited 
the advantages of technology in one or another form. 
The term ‘nanotechnology’ has also been used in 
other fields of science such as electronics, physics and 
engineering for many decades. Nanotechnology has led to 
tremendous progress in these fields. Nanotechnology is a 
multidisciplinary field, representing a convergence of the 
basic sciences and applied disciplines such as biophysics, 
molecular biology, and bioengineering (Manivannan, 
2011). It has had a powerful impact in various fields 
of medicine, including cardiology, immunology, 
ophthalmology, oncology, endocrinology and pneumology, 
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and in highly specialized areas such as gene delivery, brain 
targeting and oral vaccine formulation. Nanotechnology 
provides intelligent materials, systems and devices for 
better pharmaceutical applications (Bhattacharrya et al., 
2009; Malakar et al., 2012; Lamba, 2006).
Nanoparticles are defined as particulate dispersions 
or solid particles with size in of the range 10-100 nm. 
Drugs are dissolved, entrapped, encapsulated or attached to 
nanoparticle matrices (Mohanraj,Chen, 2006; Manmode, 
Sakarkar, Mahajan, 2009)
TYPES OF NANOSTRUCTURES
Nanosuspensions
A nanosuspension is defined as a very finely colloid, 
biphasic, dispersed, solid drug particle in an aqueous 
vehicle, of size below 1 µm, without any matrix material, 
stabilized by a surfactant and a polymer, prepared using 
a suitable method for drug delivery applications through 
various routes of administration such as the oral, topical, 
parenteral, ocular and pulmonary routes (Nagare et al., 
2012; Prabhakar, Balakrishna, 2011; Verma, Bindal, 
2012).
Solid lipid nanoparticles
Solid lipid nanoparticles are novel potential colloidal 
carrier systems used as alternative materials to polymers. 
They are identical to oil-in-water emulsions used for 
parenteral nutrition, but the liquid lipid of these emulsions 
is replaced by a solid lipid. They have good compatibility 
and low toxicity and are physically stable. Lipophilic 
drugs are better delivered using solid lipid nanoparticles 
(Ekambaram, Sathali, Priyanka, 2012; Pragati et al., 
2009).
Nanofibres
Nanofibres are defined as fibres with diameter 
less than 50–500 nm. They have an extremely high 
surface area-to-weight ratio compared with conventional 
nonwovens. Nanofibres have good filtration properties 
(Kattamuri et al., 2012; Dineshkumar et al., 2012).
Nanocomposites
 Nanocomposites have superior strength and fracture 
toughness. Nanocomposites have good mechanical, 
optical, electrical and thermal properties (Sambarkar, 
Patwekar, Dudhgaonkar, 2012).
Carbon nanotubes
Carbon nanotubes (CNTs) are allotropes of carbon. 
The length-to-diameter ratio of these nanostructures 
is greater than 1,000,000. CNTs exhibit good carrier 
properties and are used to transport biomolecules to 
target sites. These biomolecules include a diverse array 
of compounds such as drugs, vaccines, small peptides, 
proteins, nucleic acids, vitamins and sugars (Hirlekar et 
al., 2009; Mishra, 2013; Gurjar et al., 2013).
Nanopores
Materials with pore-sizes in the nanometre range 
are of special interest for a broad range of industrial 
application because of their outstanding properties with 
regard to thermal insulation and controllable material 
separation and release and their suitability as templates or 
fillers for chemistry and catalysis. Aerogels are examples 
of nonporous materials. They are produced using sol-gel 
chemistry (Wannunu, 2012).
Liposomes
Liposomes are small artificial vesicles (50‑100 nm) 
developed from phospholipids. They have been used 
as drug carriers as a result of their ability to prevent 
degradation of drugs, reduce side effects and target drugs 
to sites of action. Liposomes are used for transdermal drug 
delivery (they enhance the skin permeation of drugs of 
high molecular weight and poor water solubility) and as 
carriers for delivery of drugs (they reduce toxicity) in the 
treatment of ocular diseases (Ochekpe, 2009b).
Polymeric nanoparticles
Polymeric nanoparticles are solid colloidal particles 
with diameter ranging from 1 nm to 1000 nm. Polymeric 
nanoparticulate systems developed using biodegradable 
and biocompatible polymers offer interesting options 
for controlled drug delivery and drug targeting (Jawahar, 
Meyyanathan, 2012).
Polymeric micelles
Polymeric micelles are self-assembled core–shell 
nanostructures formed in aqueous solutions consisting 
of amphiphilic block polymers. Micelles are formed in 
aqueous solutions when the concentration of the block 
copolymer increases above a certain concentration or 
critical micelle concentration (Xu, Ling, Zhang, 2013).
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Dendrimers
Dendrimers are branched macromolecules. They 
have a central core unit with a high degree of molecular 
uniformity, a narrow molecular weight distribution, 
specific size and shape characteristics and a highly-
functionalized, terminal surface. The cellular uptake 
in dendrimers is through endocytosis, and drugs are 
bound to dendrimers within cells (Mishra, 2011; Shishu, 
Maheshwari, 2009; Trivedi et al., 2012).
Nanocapsules
Nanocapsules are vesicular or reservoir systems 
in which oil/water is essentially confined to a cavity 
surrounded by a tiny polymeric membrane. Nanocapsules 
can be targeted to specific cells and locations within 
the body after they are injected intravenously or 
subcutaneously (Dineshkumar et al., 2013).
Nanoplex
A nanoplex is a drug nanoparticle complex with 
an oppositely charged polyelectrolyte. Cationic or 
anionic drugs are made to reach with oppositely charged 
polyelectrolytes to form Nanoplex (Chew, 2012a, 
2012c).
Magnetic nanoparticles
Magnetic nanoparticles form a class of engineered 
particulate materials of particle size less than 100 nm 
that can be manipulated using external magnetic fields. 
Magnetic nanoparticles consist of a core of a polymer such 
as dextran coated with an inorganic substance such as iron 
oxide (Indira, Lakshmi, 2010).
Nanoemulsions
Nanoemuls ions/submicron emuls ions  are 
thermodynamically stable, transparent (translucent) 
dispersions of oil and water stabilized interfacial films of 
surfactant and cosurfactant molecules. Their droplet size 
is less than 100 nm (Indira, Lakshmi, 2010).
Quantum dots
Quantum dots are semiconducting materials 
consisting of a semiconductor core provided with a shell 
to improve optical properties. Their properties originate 
from their physical size, with the radius being in the 
range 10–100 Å. These have had a significant impact on 
imaging, in-vitro and in-vivo detection and analysis of 
biomolecules, immunoassay and DNA hybridization. They 
are used in non-viral vectors for gene therapy. Their main 
application is in labeling cells and as therapeutic tools for 
cancer treatment (Patel, 2012).
Carbon allotrope graphenes
Graphene is a substance made of pure carbon, with 
atoms arranged in a regular hexagonal pattern similar 
to that of graphite but in a one-atom-thick sheet. It is an 
allotrope of carbon whose structure is a single planar sheet 
of sp2-bonded carbon atoms that are densely packed in 
a honeycomb crystal lattice. Hence, graphenes may be 
considered as the mother of graphite, fullerene and CNTs 
(Bera et al., 2010).
NANOPLEX: A NEW TREND IN NANO TECH­
NOLOGY
A nanoplex is a drug nanoparticle complex with 
an oppositely charged polyelectrolyte. A cationic or 
anionic drug is made to react with an oppositely charged 
polyelectrolyte to form a nanoplex. 
Most promising candidates for drugs exhibit low-
saturation solubility in the aqueous phase. Making these 
drugs more soluble is the aim of research presently because 
these drugs exhibit low oral bioavailability. As a result, 
frequent dosing is required, imposing a pill burden and 
financial burden on patients. There are three major ways 
of enhancing bioavailability: (1) transformation of API 
into its highly soluble salt form, (2) producing crystalline 
nanoparticles (or nanoAPI) of API and (3) delivering the 
API in its amorphous form (Ando, Radebaugh, 2005)
Forming a salt of a weak organic acidic or basic drug 
is the easiest way of increasing the saturation solubility 
of the drug. But salt formation does not guarantee the 
enhancement of the saturation solubility (Rabinow, 2004). 
NanoAPI formulations are not limited to acidic or basic 
drugs because the particles are reduced to nanosize and the 
behaviour of these particles is according to the Ostwald-
Freundlich solubility theory.
The Ostwald-Freundlich equation states that 
saturation solubility enhancement by nanoionization is 
significant only for sizes much greater than 100 nm (Grant, 
Brittain, 1995). NanoAPI with sizes of ∼150-200 nm hves 
been found to exhibit an only 15% increase in saturation 
solubility over their microscale counterparts. The 
established nanoAPI formulation techniques (e.g. high-
pressure homogenization, wet milling) are not promising 
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for producing nanoAPI with size less than 100 nm. 
Therefore, advances in nanoAPI preparation techniques 
are needed to enhance bioavailability.
A different strategy to increase the apparent 
solubility is to generate a metastable state of the amorphous 
form of the API. Dissolution of the amorphous API 
results in a highly supersaturated solution, with an 
apparent solubility that is significantly greater than the 
saturation solubility of the crystalline counterparts. The 
high supersaturation level consequently enhances drug 
absorption across the gastrointestinal lumen, resulting in 
enhanced bioavailability, provided that the supersaturation 
can be maintained for a period sufficient for absorption. 
The significant thing about amorphous forms is that the 
generation of high supersaturation levels has been shown 
to translate to enhanced bioavailability in vivo (Yang, 
Johnton, Williams, 2010; Tam et al., 2008).
Amorphous API is typically prepared in the form of 
a microscale solid dispersion of the drug that is stabilized 
using high-transition-temperature polymers (e.g., 
hydroxypropylmethylcellulose (HPMC), poly(ethylene 
glycol)) by cogrinding, hot melt extrusion or antisolvent 
precipitation techniques (Yamada et al., 1999; Verreck 
et al., 2003). The stabilizer (generally up to 50% (w/w)) 
plays two important roles: (1) preventing recrystallization 
of the amorphous API during storage by occupying its 
high-energy surfaces and (2) inhibiting precipitation of 
the dissolved drug, which prolongs the supersaturation. 
However, it reduces the drug loading.
Amorphous API formulations, yet, suffer from the 
drawbacks of (1) low drug loading and (2) a strong tendency 
to recrystallize after dissolution. The latter drawback results 
in slow dissolution rates of the amorphous API, mostly when 
slowly dissolving stabilizers (e.g., HPMC) are used, leading 
to low apparent solubility. The in-solution recrystallization 
tendency can be overcome by developing a nanoscale 
formulation, in which the specific surface area leads to a 
high dissolution rate. A number of nanoscale amorphous 
API (or amorphous nanoAPIs) have been successfully 
prepared using a wide range of techniques (e.g., antisolvent 
precipitation, sonoprecipitation) with a drug loading of up 
to 90% (w/w) (Chen et al., 2006; Matteucci et al., 2006; 
Dhumal et al., 2008)). These techniques, however, have 
some weaknesses, including intricate processes, a heavy use 
of organic solvents, high expenses related to energy and a 
wide size distribution in the product.
Preparation of amorphous drug Nanoplex
Depending on the solubility (which is a function 
of pH),a drugs is dissolved in an acidic or basic aqueous 
solution to form it cation or anion, respectively. 
Amphoteric drugs forms cations when they are dissolved 
in aqueous acetic acid solutions (AA) (pH<pKa), whereas 
acidic drugs forms anions when they are dissolved 
in aqueous KOH solutions (pH>pKa). The ionized 
drug solution is subsequently added to the oppositely 
charged aqueous polyelectrolyte solution, upon which a 
drug-polyelectrolyte electrostatic interaction takes 
place to form a soluble drug-polyelectrolyte complex, 
as illustrated in figure 1. At a certain concentration, the 
value of which depends on the drug hydrophobicity, 
drug-PE complexes aggregate as a result of the interdrug 
hydrophobic interaction and finally form an insoluble drug 
nanoplex in the presence of a salt. The role of the salt is to 
provide a charge-screening effect to minimize repulsions 
of the like-charged PE chains, which can inhibit complex 
aggregation, as shown in figure 2. The strong drug–PE 
electrostatic interaction prevents the drug molecules 
from assembling into ordered crystalline structures 
upon precipitation, resulting in the amorphous nanoplex 
(Cheow, 2012c).
Advantages of Nanoplex
1. The method of preparation of Nanoplex is simple as 
only mixing of two solutions, of the drug and PE, is 
involved.
2. Nanoplex preparation does not require a heavy use 
of solvents.
FIGURE 1 - Preparation of nanoplex.
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3. The energy requirement for nanoplex preparation is 
minimal compared with other nano formulations.
4. Nanoplex formation is a fast process.
5. There is no need to use sophisticated instruments to 
prepare Nanoplex.
Mechanism of nanoplex formation
The water-insoluble drug is first dissolved in an 
acidic or basic medium to form an anionic or cationic 
drug solute. Afterwards the ionized drug solution is mixed 
with an oppositely charged polyelectrolyte solution, which 
initiates the drug–polyelectrolyte electrostatic interaction 
and simultaneously charge neutralization as shown 
in figure 3. The drug solute is transformed back to its 
sparingly soluble form upon charge neutralization, leading 
to a loss of solubility, and hence there is rapid precipitation 
and formation of the nanoscale drug–polyelectrolyte 
complex. The combination of rapid precipitation and 
strong electrostatic interactions between the drug and 
the polyelectrolyte prevents the drug molecules from 
assembling into ordered crystalline structures. As a result, 
an amorphous drug-polyelectrolyte nanoparticle complex 
is formed (Cheow, 2012b).
Role of salt in nanoplex preparation
The salt plays an important role in the self-assembly 
of the nanoplex through its electrostatic charge shielding 
FIGURE 2 - Role of salt in nanoplex formulation.
FIGURE 3­ Mechanism of nanoplex formulation. 
function. In the absence of salt, intermolecular repulsions 
between the like-charged PE chains inhibit their spatial 
interactions. The same can be said for the drug, with the 
charged drug molecules repelling if there is no salt, thus 
hindering a compact assembly of drug molecules. The higher 
solubility of the drug in a solution of lower ionic strength 
further contributes to the lack of inter-drug hydrophobic 
interactions (Singh, Caram-Lelham, 1998). Consequently, 
there is no nanoplex precipitation in the absence of a salt 
despite the oppositely charged interactions. Instead, soluble 
drug-PE complexes may be present, reminiscent of the 
soluble amphiphilic drug and PEs previously investigated. 
In the presence of a salt, the shielding of charge enables the 
PE chains to be in closer contact with each other. Likewise, 
the drug molecules are also in closer contact, which leads 
to the formation of a core-shell nanoplex, which then 
precipitates upon drug. Nevertheless, the charge-shielding 
effect of the salt must not be too strong, or it will (i) inhibit 
the electrostatic interactions between the drug molecules 
and PE involved in complex formation or (ii) neutralize the 
charge interactions between the drug and PE in the already-
formed complex, resulting in de-complexation (Hugerth, 
Sandlot, 2001).
Evaluation of Nanoplex
·	 Complexation efficiency. This is defined as the 
mass of a drug that forms a complex with the poly-
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electrolyte relative to the initially added drug. It is 
calculated by measuring the optical density of the 
supernatant after the first centrifugation of the nano-
plex suspension (Cheow, 2012c).
·	 Production yield. It is the ratio of the weight of 
the drug and polyelectrolyte initially added to the 
weight of the dry nanoplex formed after freeze dry-
ing (Cheow, 2012c).
·	 Drug loading. This is the actual amount of drug 
present in the nanoplex powder. It is calculated by 
dissolving 5 mg of the nanoplex powder in 20 ml 
of ethanol and measuring the absorbance of the 
solution after centrifugation and filtration (Cheow, 
2012c).
·	 Particle size analysis. The particle size of the nano-
plex is analysed using a particle size analyser (Chew, 
2012c).
·	 Zeta potential. The zeta potential of the nanoplex is 
determined using a zetasizer (Cheow, 2012a).
·	 Differential scanning calorimetry (DSC). DSC is 
performed to determine the interactions between 
the drug and polyelectrolyte. The interactions are 
also determined on the basis of their melting points, 
and the difference is calculated using a DSC instru-
ment. The results are presented in the form of graphs 
(Cheow, 2012c).
·	 Powder X-ray diffraction. Powder X-ray diffraction 
patterns of samples are determining using a powder 
X-ray diffractometer. This gives an idea about the 
nature of the sample (Cheow, 2012a).
·	 Scanning electron microscopy. The surface mor-
phology of the sample is observed using a scanning 
electron microscope (Cheow, 2012c).
·	 Dissolution study. Dissolution testing of the nano-
plex is carried out using the dialysis bag method to 
determine the drug release (Cheow, 2012c).
·	 Saturation solubility study. The solubility of the drug 
and that of the formulation are determined using the 
orbital flask shaker method. The concentration of 
the drug is determined from the absorbance, through 
spectrophotometric analysis (Cheow, 2012c).
·	 Stability study. The stability of the nanoplex is 
tested by placing it in an environmental stability 
chamber, and its drug content is determined (Cheow, 
2012c).
Applications of Nanoplex
Enhancement of solubility and dissolution rate
Preparing Nanoplex of poorly water-soluble drugs 
(i.e., class II and class IV drugs) enhances their solubility 
and dissolution rate and ultimately bioavailability. 
Solubility enhancement reduces the dose requirement of 
a drug (Cheow, 2012c).
Drug delivery to the brain
The blood brain barrier (BBB) is the most important 
factor limiting the development of a new drug for the 
central nervous system. The BBB is characterized by 
relatively impermeable endothelial cells with tight 
junctions, enzymatic activity and active efflux transport 
systems. It effectively prevents the passage of water-
soluble molecules from the blood circulation into the 
CNS and can reduce the concentration of lipid-soluble 
molecules in the brain through the action of enzymes 
or efflux pumps. Consequently, the BBB only permits 
selective transport of those molecules that are essential 
for brain function. It has been suggested that nanoparticles 
may be used as non-viral gene delivery vectors and that 
they have great potential in therapeutic applications for 
several diseases such as HIV-1, AIDS, dementia and 
cerebral ischaemia. Nanoplex have been evaluated for the 
specificity and efficiency of quantum dot (QD) complexes 
[with MMP-9-siRNA (nanoplex) in down-regulating 
the expression of the MMP-9 gene in the brain micro 
vascular endothelial cells (BMVECs) that constitute the 
BBB. Adela Bonoiu et al. demonstrated the use of a novel 
nanoplex siRNA delivery system in modulating MMP-9 
activity in BMVECs and other MMP-9-producing cells. 
This application will prevent neuroinflammation and 
maintain the integrity of the BBB (Bonoiu, et al., 2009 ).
Nanoplex for gene delivery
Non-viral vector-mediated gene therapy is currently 
one of the most attractive strategies used due to their 
biocompatibility, biodegradability, minimal cytotoxicity, 
lack of pathogenicity and low immunogenicity. The 
development of non-viral vectors consisting of dendrimers, 
liposomes and cationic polymers is the focus of research 
currently. Cationic polymers have been found to be useful 
in neutralizing the anionic nature of DNA, thus efficiently 
condensing DNA and allowing it to enter cells easily. 
Cationic polymers represent an interesting class of vectors 
in plasmid DNA delivery formulations. Various cationic 
polymers including synthetic amino acid polymers such as 
poly(1-lysine) and polyethyleneimine (PEI), natural DNA-
binding proteins such as histones, carbohydrate-based 
polymers such as chitosan and various dextran derivatives 
have been reported (Thomas, 2010b).
Drug targeting in cancer treatment
Many different cationic lipids have been synthesized 
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for non-viral vectors. The general structure of a cationic 
lipid has three parts: (1) a hydrophobic lipid anchor group, 
which helps form the micellar structure and can interact 
with cell membranes; (2) a linker group, such as an ester, 
an amido group or a carbamate; and (3) a positively 
charged head-group, mainly composed of cationic amines. 
Cationic cholesterol derivatives could be selected as the 
anchor group because of their high transfection activity 
and low toxicity. The linker group of cationic cholesterol 
derivatives controls the conformational flexibility, degree 
of stability, biodegradability and gene transfection 
efficiency. Cationic nanoparticles composed of OH‑Chol 
(NP-OH) could deliver siRNA with a high transfection 
efficiency in vitro when the nanoparticle/siRNA complex 
(nanoplex) is formed in an NaCl solution (Hattori et al., 
2008).
Drug delivery of proteins and peptides
Significant advances in biotechnology and 
biochemistry have led to the discovery of a large number 
of bioactive molecules and vaccines based on peptides 
and proteins. The development of suitable carriers 
remains a challenge because the epithelial barrier of the 
gastrointestinal tract limits the bioavailability of these 
molecules and they are susceptible to gastrointestinal 
degradation by digestive enzymes. Proteins are charged 
molecule that forms a complex with polyelectrolyte 
therefore, they are suitable candidate for nanoplex 
formulation (Woitiski, Ribeiro, Neufeld, 2007; Ranjan et 
al., 2010).
CONCLUSION
Most orally administered drugs are amphiphilic 
in nature and soluble in a weak acid or base. They can 
be transformed into amorphous Nanoplex by the simple 
complexation method. The preparation of a nanoplex 
requires only the mixing of two solutions at ambient 
conditions. It is also solvent-free and fast. It requires little 
energy and produces uniform-sized nanoparticles with a 
high complexation efficiency, drug loading and production 
yield.
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